Anticoagulation in portal vein thrombosis among patients with cirrhosis; myths vs evidence (ondemand)-Anticoagulation od

Video Transcription

Video Summary

The webinar reviewed current evidence and practical management of portal vein thrombosis (PVT) in patients with cirrhosis. Jessica Davis discussed when to anticoagulate, treatment choices, and management challenges; Marco Senzolo focused on bleeding risk.<br /><br />Anticoagulation is most clearly beneficial for recent, extensive or highly occlusive PVT, particularly in liver-transplant candidates, where preserving the portal vein can enable a physiologic transplant connection. Some clots resolve spontaneously, while longstanding, completely occlusive clots are less likely to recanalize. Decisions for less extensive or chronic PVT should be individualized.<br /><br />Potential agents include direct oral anticoagulants, warfarin, and low-molecular-weight heparin. Choice depends on liver-disease severity, kidney function, patient preference, and transplant plans; DOACs should generally be avoided in Child-Pugh C cirrhosis. Evidence suggests anticoagulation increases recanalization and may reduce mortality and portal-hypertensive complications. Bleeding risk is influenced more by disease severity and comorbidities—such as kidney dysfunction and infection—than by standard coagulation tests or platelet count alone. Treating PVT may lower, rather than increase, portal-hypertensive bleeding risk.<br /><br />Treatment is generally continued for at least six months after recanalization and often longer, especially for transplant candidates. Guidance for holding anticoagulation around procedures remains limited; speakers emphasized minimizing interruptions and restarting promptly when clinically appropriate. TIPS can improve portal flow and help recanalize PVT, particularly when there is another indication or transplant feasibility is threatened; anticoagulation may not be needed after successful TIPS. The speakers noted that more research is needed to clarify optimal dosing, duration, and procedural management.

Keywords

portal vein thrombosis

cirrhosis

anticoagulation

recanalization

bleeding risk

direct oral anticoagulants

warfarin

low-molecular-weight heparin

liver transplant candidates

TIPS